X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-03-03 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.55 | -13,609 | 54,284 | -20% | -$1,028,165 | |||||
2023-03-03 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $76.16 | -21,421 | 124,799 | -15% | -$1,631,411 | ||||||
2023-03-03 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $76.16 | -25,635 | 209,753 | -11% | -$1,952,346 | ||||||
2023-03-03 | NVCR | Cordova Ashley | CFO | S - Sale | $76.16 | -5,505 | 101,310 | -5% | -$419,257 | ||||||
2023-03-03 | NVCR | Burke William Patrick | CHRO | S - Sale | $76.16 | -593 | 66,090 | -1% | -$45,163 | ||||||
2023-03-02 | NVCR | Burke William Patrick | CHRO | S - Sale | $75.28 | -281 | 66,683 | 0% | -$21,153 | ||||||
2023-03-02 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $75.28 | -937 | 146,220 | -1% | -$70,535 | ||||||
2023-03-02 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $75.28 | -1,213 | 235,388 | -1% | -$91,312 | ||||||
2023-03-02 | NVCR | Cordova Ashley | CFO | S - Sale | $75.28 | -1,055 | 106,815 | -1% | -$79,418 | ||||||
| M | 2023-03-02 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.95 | -2,903 | 67,893 | -4% | -$223,393 | |||||
2023-03-02 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.38 | -4,107 | 58,988 | -7% | -$309,578 | ||||||
| D | 2023-03-01 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $76.36 | -1,684 | 63,095 | -3% | -$128,594 | |||||
| D | 2023-03-01 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale+OE | $76.36 | -1,923 | 99,975 | -2% | -$146,845 | |||||
| D | 2023-03-01 | NVCR | Cordova Ashley | CFO | S - Sale+OE | $76.36 | -2,198 | 96,062 | -2% | -$167,845 | |||||
| D | 2023-03-01 | NVCR | Burke William Patrick | CHRO | S - Sale+OE | $76.36 | -755 | 66,964 | -1% | -$57,654 | |||||
| D | 2023-03-01 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale+OE | $76.36 | -2,164 | 184,615 | -1% | -$165,248 | |||||
| D | 2023-01-05 | NVCR | Weinberg Uri | Chief Science Officer | S - Sale+OE | $116.14 | -8,143 | 43,286 | -16% | -$945,756 | |||||
| D | 2023-01-05 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $112.25 | -39,507 | 46,158 | -46% | -$4,434,654 | |||||
2023-01-05 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $108.00 | -387 | 82,843 | 0% | -$41,796 | ||||||
| D | 2023-01-05 | NVCR | Danziger Asaf | CEO | S - Sale+OE | $108.74 | -212,500 | 13,622 | -94% | -$23,106,230 | |||||
2022-10-13 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.01 | -6,754 | 43,626 | -13% | -$513,372 | ||||||
2022-10-06 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $84.37 | -6,754 | 50,380 | -12% | -$569,835 | ||||||
2022-09-29 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.35 | -6,754 | 57,134 | -11% | -$522,422 | ||||||
2022-09-22 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.00 | -6,754 | 63,888 | -10% | -$520,058 | ||||||
| D | 2022-09-15 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale+OE | $88.52 | -12,271 | 70,642 | -15% | -$1,086,222 | |||||
| A | 2022-09-08 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $81.48 | -6,754 | 77,396 | -8% | -$550,316 | |||||
2022-09-09 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $88.00 | -1,863 | 84,150 | -2% | -$163,944 | ||||||
2022-09-06 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $78.57 | -1,384 | 86,013 | -2% | -$108,741 | ||||||
2022-09-02 | NVCR | Burke William Patrick | CHRO | S - Sale | $79.04 | -718 | 55,486 | -1% | -$56,749 | ||||||
2022-09-02 | NVCR | Cordova Ashley | CFO | S - Sale | $79.04 | -885 | 72,376 | -1% | -$69,948 | ||||||
2022-09-02 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $79.04 | -296 | 165,024 | 0% | -$23,395 | ||||||
2022-09-02 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $79.04 | -269 | 83,230 | 0% | -$21,261 | ||||||
| M | 2022-09-01 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $77.50 | -14,796 | 87,397 | -14% | -$1,146,634 | |||||
2022-08-03 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale | $73.73 | -5,959 | 28,672 | -17% | -$439,328 | ||||||
2022-08-02 | NVCR | Doyle William F | Exec COB | S - Sale | $69.66 | -837 | 551,176 | 0% | -$58,305 | ||||||
2022-08-02 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale | $69.66 | -437 | 34,631 | -1% | -$30,441 | ||||||
2022-08-02 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $69.66 | -414 | 102,193 | 0% | -$28,839 | ||||||
2022-06-10 | NVCR | Hilleman Jeryl L | Dir | S - Sale | $69.61 | -407 | 2,537 | -14% | -$28,331 | ||||||
| M | 2022-05-10 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale | $63.17 | -4,205 | 34,846 | -11% | -$265,646 | |||||
| D | 2022-03-09 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale+OE | $71.19 | -3,669 | 83,187 | -4% | -$261,196 | |||||
| M | 2022-03-07 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $69.73 | -7,775 | 81,908 | -9% | -$542,116 | |||||
2022-03-08 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $70.10 | -744 | 102,295 | -1% | -$52,154 | ||||||
2022-03-08 | NVCR | Burke William Patrick | CHRO | S - Sale | $70.10 | -1,037 | 55,991 | -2% | -$72,694 | ||||||
2022-03-08 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $70.10 | -2,923 | 165,102 | -2% | -$204,902 | ||||||
2022-03-08 | NVCR | Cordova Ashley | CFO | S - Sale | $70.10 | -759 | 60,848 | -1% | -$53,206 | ||||||
2022-03-08 | NVCR | Longsworth Todd Christopher | GC | S - Sale | $70.10 | -2,339 | 62,462 | -4% | -$163,964 | ||||||
2022-03-08 | NVCR | Doyle William F | Exec COB | S - Sale | $70.10 | -2,385 | 552,013 | 0% | -$167,189 | ||||||
| DM | 2022-03-03 | NVCR | Longsworth Todd Christopher | GC | S - Sale+OE | $71.87 | -3,067 | 64,801 | -5% | -$220,414 | |||||
| DM | 2022-03-03 | NVCR | Cordova Ashley | CFO | S - Sale+OE | $73.16 | -1,705 | 61,607 | -3% | -$124,744 | |||||
| DM | 2022-03-03 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale+OE | $72.54 | -5,543 | 89,683 | -6% | -$402,064 | |||||
| DM | 2022-03-03 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale+OE | $71.83 | -2,313 | 43,257 | -5% | -$166,136 | |||||
| DM | 2022-03-03 | NVCR | Burke William Patrick | CHRO | S - Sale+OE | $71.43 | -1,367 | 57,028 | -2% | -$97,641 | |||||
| DM | 2022-03-03 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale+OE | $71.78 | -3,870 | 168,025 | -2% | -$277,797 | |||||
| DM | 2022-03-03 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale+OE | $72.97 | -1,485 | 103,039 | -1% | -$108,359 | |||||
| D | 2022-01-03 | NVCR | Burke William Patrick | CHRO | S - Sale+OE | $76.00 | -3,951 | 50,870 | -7% | -$300,263 | |||||
2021-11-26 | NVCR | Danziger Asaf | CEO | P - Purchase | $102.44 | +4,974 | 13,276 | +60% | +$509,539 | ||||||
2021-11-02 | NVCR | Cordova Ashley | CFO | S - Sale | $107.28 | -209 | 41,758 | 0% | -$22,421 | ||||||
2021-09-02 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $138.23 | -540 | 87,153 | -1% | -$74,645 | ||||||
2021-09-02 | NVCR | Cordova Ashley | CFO | S - Sale | $138.23 | -828 | 41,967 | -2% | -$114,456 | ||||||
2021-09-02 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $138.23 | -181 | 149,899 | 0% | -$25,020 | ||||||
| M | 2021-09-02 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $138.57 | -657 | 73,512 | -1% | -$91,041 | |||||
| D | 2021-08-12 | NVCR | Cordova Ashley | CFO | S - Sale+OE | $140.94 | -26,624 | 44,260 | -38% | -$3,752,286 | |||||
2021-08-05 | NVCR | Madden Martin J. | Dir | S - Sale | $153.13 | -34 | 16,004 | 0% | -$5,206 | ||||||
2021-08-04 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $148.71 | -2,063 | 74,169 | -3% | -$306,789 | ||||||
| D | 2021-08-05 | NVCR | Leung Gabriel | Dir | S - Sale+OE | $152.50 | -1,000 | 72,859 | -1% | -$152,500 | |||||
| M | 2021-08-02 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $149.39 | -1,041 | 89,158 | -1% | -$155,520 | |||||
2021-08-03 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $149.43 | -1,654 | 76,232 | -2% | -$247,157 | ||||||
2021-08-02 | NVCR | Doyle William F | Exec COB | S - Sale | $149.38 | -995 | 554,398 | 0% | -$148,631 | ||||||
2021-08-03 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale | $150.11 | -464 | 28,144 | -2% | -$69,651 | ||||||
| DM | 2021-07-30 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale+OE | $154.63 | -1,187 | 28,608 | -4% | -$183,550 | |||||
| D | 2021-07-06 | NVCR | Leung Gabriel | Dir | S - Sale+OE | $183.54 | -1,000 | 72,859 | -1% | -$183,540 | |||||
2021-06-10 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $215.00 | -23,540 | 77,732 | -23% | -$5,061,100 | ||||||
| D | 2021-06-07 | NVCR | Leung Gabriel | Dir | S - Sale+OE | $204.55 | -1,000 | 72,045 | -1% | -$204,550 | |||||
| D | 2021-05-27 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale+OE | $200.00 | -1,833 | 29,054 | -6% | -$366,600 | |||||
2021-05-12 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale | $180.48 | -1,943 | 29,054 | -6% | -$350,673 | ||||||
| DM | 2021-05-10 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale+OE | $184.39 | -4,095 | 30,997 | -12% | -$755,055 | |||||
| D | 2021-05-10 | NVCR | Weinberg Uri | Chief Science Officer | S - Sale+OE | $189.65 | -5,650 | 31,667 | -15% | -$1,071,523 | |||||
2021-05-05 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $199.67 | -1,290 | 101,272 | -1% | -$257,574 | ||||||
| D | 2021-05-05 | NVCR | Leung Gabriel | Dir | S - Sale+OE | $199.67 | -1,000 | 72,045 | -1% | -$199,670 | |||||
| D | 2021-05-04 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale+OE | $200.86 | -1,043 | 102,562 | -1% | -$209,493 | |||||
2021-04-13 | NVCR | Doyle William F | Exec COB | S - Sale | $199.55 | -95,000 | 555,393 | -15% | -$18,957,452 | ||||||
2021-04-13 | NVCR | Danziger Asaf | CEO | S - Sale | $196.34 | -97,973 | 8,184 | -92% | -$19,236,323 | ||||||
| D | 2021-04-13 | NVCR | Leung Gabriel | Dir | S - Sale+OE | $198.84 | -6,000 | 72,045 | -8% | -$1,193,035 | |||||
| D | 2021-04-13 | NVCR | Benaim Ely | Chief Medical Officer | S - Sale+OE | $200.00 | -5,958 | 33,259 | -15% | -$1,191,600 | |||||
| A | 2021-03-23 | NVCR | Weinberg Uri | Chief Science Officer | S - Sale | $140.00 | -2,835 | 33,471 | -8% | -$396,900 | |||||
2020-02-28 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $72.22 | -3,670 | 150,014 | -2% | -$265,029 | ||||||
| D | 2021-04-01 | NVCR | Doyle William F | Exec COB | S - Sale+OE | $134.12 | -7,928 | 650,393 | -1% | -$1,063,303 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |